FDA Approves KLYGEFA™ for Generalized Myasthenia Gravis

Oculopharyngeal Muscular Dystrophy (OPMD)

Research

Researchers are studying OPMD to better understand how changes in the PABPN1 gene lead to muscle weakness and to identify potential treatments.

Current research includes approaches that target the underlying genetic cause of OPMD, including gene therapy and gene-targeted therapies. Researchers are also investigating ways to reduce the effects of abnormal PABPN1 protein and preserve muscle function.

Several potential treatments are being evaluated in clinical studies to assess their safety and potential benefits. While there is currently no approved disease-modifying treatment for OPMD, ongoing research continues to expand understanding of the disease and advance new treatment approaches.

Last reviewed October 2026.

Looking for more information, support or ways to get involved?

Find MDA
in your Community